T cells are central to the body's defense ... anti-tumor immunity is an emerging area in cancer therapy, systemically inhibiting Tregs can cause severe autoimmune reactions. This challenge has ...
UK start-up Quell Therapeutics has secured a partnership with AstraZeneca focused on cell therapies for autoimmune diseases, with an $85 million upfront payment and which could be worth up to $2 ...
It highlights the strong commitment and rapid integration of our respective research teams as well as providing important early validation of our novel CAR-Treg cell therapy approach to autoimmune ...